Investor Presentation Q1 2022

17 Investor presentation First three months of 2022 Financial results - First three months of 2022 Novo NordiskⓇ In DKK million Sales Gross profit Gross margin Sales and distribution costs Percentage of sales Research and development costs Percentage of sales First three months of 2022 42,031 First three months of 2021 33,804 Change Change (reported) (CER) 24% 18% 35,114 83.5% (10,183) 24.2% 27,993 25% 18% 82.8% (8,256) 23% 18% 24.4% (5,206) (3,944) 32% 29% 12.4% 11.7% Administration costs (970) (932) 4% 2% Percentage of sales 2.3% 2.8% Other operating income and expenses 392 121 224% 204% Operating profit 19,147 14,982 28% 18% Operating margin 45.6% 44.3% Financial items (net) (1,228) 956 Profit before income tax 17,919 15,938 12% Income taxes (3,709) (3,315) 12% Effective tax rate 20.7% 20.8% Net profit 14,210 12,623 13% Diluted earnings per share (DKK) 6.22 5.45 CER: Constant exchange rates

View entire presentation